A dual GLP-1/GIP receptor agonist (Mounjaro/Zepbound). SURMOUNT-5 trial (2025) showed 20.2% weight loss at 72 weeks, outperforming semaglutide head-to-head.
A GLP-1 receptor agonist (Ozempic/Wegovy). SURMOUNT-5 trial showed 13.7% weight loss at 72 weeks. SELECT trial confirmed 20% cardiovascular risk reduction.
A triple-agonist (GLP-1/GIP/glucagon). TRIUMPH-4 Phase 3 trial (Dec 2025) showed 28.7% weight loss at 68 weeks - highest of any obesity medication. FDA approval expected 2027.
A dual glucagon/GLP-1 receptor agonist in development for obesity and NASH. Shows promising metabolic benefits.
A long-acting amylin analogue that reduces appetite and slows gastric emptying. Often combined with semaglutide.
A daily GLP-1 agonist marketed as Victoza/Saxenda. First GLP-1 approved for weight management.
A modified fragment of HGH (amino acids 176-191). Targets fat metabolism without affecting blood sugar or IGF-1. TGA approved in Australia for osteoarthritis.
A mitochondrial-derived peptide that enhances metabolic function and exercise capacity. Shows promise for obesity and diabetes.
Also known as IBI362, a dual GLP-1/glucagon receptor agonist in development showing strong weight loss results.
Growth Differentiation Factor 15, a stress-response hormone that suppresses appetite through brainstem signaling.
A proapoptotic peptide that targets blood vessels supplying fat tissue, causing fat cell death. Experimental.
A mitochondrial-derived peptide with neuroprotective and metabolic benefits. Shows promise for aging and metabolic disease.
Synthetic version of the native hormone that raises blood sugar and promotes fat breakdown. Used in dual-agonist research.
Islet amyloid polypeptide, co-secreted with insulin. Slows gastric emptying and promotes satiety.
A synthetic amylin analogue marketed as Symlin. Approved for diabetes, helps with appetite and blood sugar.
A dual GLP-1/glucagon receptor agonist naturally produced in the gut. Predecessor to modern dual-agonists.
Also known as Exendin-4, the first GLP-1 receptor agonist. Derived from Gila monster venom.
FDA-approved (Vyleesi) melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women. Works on brain pathways, not hormones.
A once-daily GLP-1 receptor agonist marketed as Adlyxin. Often combined with basal insulin.
A modified GHRH analog providing pulsatile GH release. Best combined with a GHRP like ipamorelin. Mimics natural GH secretion patterns.
Long-acting GHRH analog with Drug Affinity Complex for sustained GH elevation over days.
A highly selective GH secretagogue. Does not significantly affect cortisol, prolactin, or ACTH - cleanest GHRP available. Best paired with CJC-1295.
Potent GH secretagogue binding ghrelin receptors. Stronger GH pulse than ipamorelin but more side effects. Best paired with a GHRH like CJC-1295.
Growth Hormone Releasing Peptide-6, known for strong GH release and significant appetite stimulation.
One of the most potent GH secretagogues available. Strong GH release but causes desensitization.
FDA-approved GHRH analog (Egrifta). Clinical trials show 15-18% visceral fat reduction. Also studied for cognitive benefits in HIV and aging populations.
GHRH fragment 1-29, one of the first GHRH analogs. Promotes natural GH production pattern.
An oral non-peptide GH secretagogue (not technically a peptide). Provides sustained 24-hour GH/IGF-1 elevation. Extensively studied but not FDA approved.
A myostatin inhibitor that blocks the muscle-limiting protein myostatin. Promotes significant muscle growth.
A shorter-acting variant of follistatin that inhibits myostatin with potentially different tissue targeting.
A soluble activin receptor type IIB fusion protein. Traps myostatin and related proteins.
A truncated form of IGF-1 that is 10x more potent and acts faster. Targets local muscle growth.
Long-acting variant of IGF-1 with extended half-life. Promotes muscle growth and fat loss systemically.
Pegylated Mechano Growth Factor with extended half-life. Promotes muscle satellite cell activation.
A splice variant of IGF-1 that activates muscle satellite cells. Short-acting, requires local injection.
The lipolytic fragment of human growth hormone. Specifically targets fat burning without other GH effects.
Body Protection Compound-157, a gastric pentadecapeptide. Animal studies show remarkable healing across multiple tissue types. Limited human pilot studies as of 2025. WADA banned.
An oral ghrelin receptor agonist developed for cancer cachexia. Increases appetite and lean body mass.
An FDA-approved oral GH secretagogue used for diagnosing adult GH deficiency.
Synthetic fragment of Thymosin Beta-4. Has human clinical trial data for wound and cardiac repair. Often stacked with BPC-157 ('Wolverine stack'). WADA banned.
The full 43-amino acid peptide from which TB-500 is derived. Promotes wound healing and tissue repair.
Copper tripeptide naturally found in human plasma. Extensive research on wound healing, collagen synthesis, and skin regeneration. Available as injection or topical.
Anti-inflammatory tripeptide derived from alpha-MSH. Shows promise for gut health and inflammation.
An erythropoietin-derived tissue protective peptide that reduces inflammation and promotes repair without affecting red blood cells.
Approved in 35+ countries (Zadaxin) for hepatitis and as cancer adjuvant. Enhances T-cell function and immune surveillance. Well-studied immune modulator.
A tight junction regulator that reduces intestinal permeability. Developed for celiac disease.
A neuropeptide with wide-ranging effects on immune function, inflammation, and circadian rhythm.
A human antimicrobial peptide (cathelicidin) with broad-spectrum antimicrobial and immunomodulatory effects.
A tetrapeptide (Epitalon) studied for telomerase activation. Russian research shows potential lifespan extension. Regulates melatonin and pineal gland function.
A short dipeptide bioregulator that supports immune function and thymus health.
A cartilage bioregulator peptide that supports joint health and cartilage regeneration.
A pancreatic bioregulator that supports pancreas function and metabolic health.
Russian-approved nootropic (ACTH 4-10 analog). Clinical use for stroke, cognitive decline, and optic nerve disorders. Increases BDNF and NGF.
Russian-developed anxiolytic peptide based on tuftsin. Approved in Russia for anxiety/depression. Modulates GABA, serotonin, dopamine without sedation.
A more potent, modified version of Semax with improved stability and enhanced nootropic effects.
A more potent, modified version of Selank with enhanced anxiolytic and nootropic properties.
An angiotensin IV analog with powerful nootropic effects. Million times more potent than BDNF for synapse formation.
A peptide mixture derived from pig brain with neurotrophic properties. Used clinically for stroke and dementia.
A neuropeptide mixture with brain-protective properties. Used in Russia for various neurological conditions.
A cerebrolysin-derived peptide that promotes neurogenesis and enhances BDNF activity.
An NCAM-derived peptide that promotes synaptic plasticity and has shown benefits in cognitive research.
A peptide-derived nootropic (dipeptide analog) with anxiolytic and cognitive enhancing effects. 1000x more potent than piracetam.
The 'bonding hormone' that enhances social behavior, trust, and has anxiolytic properties.
A neuropeptide that promotes delta wave sleep and has stress-reducing properties.
Antidiuretic hormone with cognitive effects. Enhances memory and attention.
A short neuropeptide bioregulator that supports brain function and normalizes sleep patterns.
A synthetic alpha-MSH analog that increases melanin production. FDA approved for certain conditions.
A potent alpha-MSH analog known for tanning, appetite suppression, and libido effects.
A peptide that stimulates GnRH release, regulating testosterone and LH. Research for reproductive health.
Synthetic gonadotropin-releasing hormone that stimulates LH and FSH. Used for fertility and TRT support.
A potent GnRH agonist that initially stimulates then suppresses gonadotropins. Used medically for various conditions.
An anti-wrinkle octapeptide that inhibits muscle contraction, similar to botox but topical.
An anti-wrinkle peptide that inhibits SNARE complex formation, reducing muscle contraction and wrinkles.
A palmitoyl pentapeptide combination that stimulates collagen and reduces wrinkle depth.
A senolytic peptide that selectively induces apoptosis in senescent cells. Cutting-edge anti-aging research.
A thymic bioregulator that modulates immune function and has remarkable anti-aging effects.
A liver and immune bioregulator peptide that supports hepatic function and DNA repair.
A vascular bioregulator that supports blood vessel health and endothelial function.
An immune bioregulator that supports overall immune function and resistance to infection.
A liver bioregulator peptide that supports hepatic function and metabolic processes.
A testicular bioregulator that supports reproductive and hormonal function in males.
A respiratory bioregulator that supports lung and bronchial health.
A respiratory bioregulator peptide that supports lung tissue and respiratory health.
A retinal bioregulator that supports eye health and visual function.
A pineal gland bioregulator that supports melatonin production and circadian rhythm.
A thymus bioregulator that supports immune function and thymic health.
A dipeptide immune stimulant that supports thymus function and immune response.
A synthetic ERRα/γ agonist that mimics the metabolic effects of exercise. Known as an 'exercise mimetic' that activates pathways normally triggered by physical activity.
